Last updated: 18 August 2022 at 7:37pm EST

Aaron G.L.Bios Equity Partn... Net Worth




The estimated Net Worth of Aaron G.L.Bios Equity Partn... is at least $167 mil dollars as of 17 August 2022. Aaron Partn owns over 50,000 units of In8 Bio stock worth over $167,371 and over the last 2 years Aaron sold INAB stock worth over $0.

Aaron Partn INAB stock SEC Form 4 insiders trading

Aaron has made over 2 trades of the In8 Bio stock since 2022, according to the Form 4 filled with the SEC. Most recently Aaron bought 50,000 units of INAB stock worth $96,500 on 17 August 2022.

The largest trade Aaron's ever made was buying 1,773,684 units of In8 Bio stock on 16 August 2022 worth over $3,370,000. On average, Aaron trades about 911,842 units every 1 days since 2022. As of 17 August 2022 Aaron still owns at least 553,110 units of In8 Bio stock.

You can see the complete history of Aaron Partn stock trades at the bottom of the page.



Insiders trading at In8 Bio

Over the last 3 years, insiders at In8 Bio have traded over $0 worth of In8 Bio stock and bought 5,038,673 units worth $10,468,296 . The most active insiders traders include Aaron G.L.Bios Equity Partn..., Leslie W.Bios Fund Ii Nt, L..., eEmily Transcend Partners Op.... On average, In8 Bio executives and independent directors trade stock every 32 days with the average trade being worth of $63,860. The most recent stock trade was executed by Jeremy R. Graff on 13 September 2023, trading 2,500 units of INAB stock currently worth $2,375.



What does In8 Bio do?

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.



What does In8 Bio's logo look like?

In8 Bio, Inc. logo

Complete history of Aaron Partn stock trades at In8 Bio

Data
#
Companhia
Acionista maioritário
Trans.
Transação
Ações Preço por ação Preço total Ações após Fonte
17 Aug 2022 Aaron G.L.Bios Equity Partn...
Comprar 50,000 $1.93 $96,500
17 Aug 2022
553,110
16 Aug 2022 Aaron G.L.Bios Equity Partn...
Comprar 1,773,684 $1.90 $3,370,000
16 Aug 2022
540,287


In8 Bio executives and stock owners

In8 Bio executives and other stock owners filed with the SEC include: